Seeking Alpha

Stone Fox Capital's  Instablog

Stone Fox Capital
Send Message
Stone Fox Capital Advisors is a registered investment advisor founded in 2010. The firm offers portfolio management with a focus on opportunistic stocks providing secular growth trends at an affordable value. An emphasis is placed on fundamental analysis though charts are used for timing entry... More
My company:
Stone Fox Capital
My blog:
Out Fox The Street
  • Savient Pharma Gets Permanent J-Code For KRYSTEXXA 0 comments
    Jan 6, 2012 3:42 PM | about stocks: SVNTQ
    Effective January 1st, KRYSTEXXA was assigned permanent J-code J2507 by the Centers for Medicare and Medicaid Services (CMS). This code allows healthcare providers an easier and quicker method for getting reimbursed for KRYSTEXXA infusions.

    While already known that KRYSTEXXA would get the permanent code on January 1st, confirmation is always good. Saivent Pharma (SVNT) had a horrible 2011 due to slow sales from this new drug approved for treatment for refractory chronic gout (RCG).

    The J code will undoubtedly help. By all accounts, the new drug works and the only issue has been working out the reimbursement process. Considering the time it takes to work through the system, SVNT doesn't expect a major impact until Q2.

    At just $2.4 and with a market cap around $170M, SVNT has become an extremely cheap stock if this J code solves all the issues with sales. It seems bizarre that this would solve the problems, but it is an expensive drug.

    Via SVNT PR:

    • product-specific billing code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available on January 1, 2012 . The new J-code, J2507, was assigned by the Centers for Medicare and Medicaid Services (CMS) and will help simplify the billing and reimbursement process for prescribers of KRYSTEXXA, the first and only U.S. Food and Drug Administration (FDA) approved treatment for refractory chronic gout (RCG).
    • "The availability of a permanent J-code for KRYSTEXXA is a significant step toward ensuring that healthcare providers and their patients with severe and debilitating gout, or RCG, have access to the first and only product for RCG," said John H. Johnson , Chief Executive Officer and President of Savient Pharmaceuticals.

    Remember this stock was over $11 back in April.

     

     






















    Disclosure: I am long SVNT.
    Stocks: SVNTQ
Back To Stone Fox Capital's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.